Aerocrine AB (AEROb.ST)

AEROb.ST on Stockholm Stock Exchange

1.10SEK
23 Dec 2014
Price Change (% chg)

-- (--)
Prev Close
1.10kr
Open
1.12kr
Day's High
1.15kr
Day's Low
1.00kr
Volume
3,669,717
Avg. Vol
510,686
52-wk High
7.85kr
52-wk Low
1.00kr

AEROb.ST

Chart for AEROb.ST

About

Aerocrine AB is a Sweden-based company engaged in the healthcare sector. The Company specializes in selling medical technology products and tests used in inflammatory airway diseases, such as asthma, which are based on the exhaled nitric oxide (FeNO) monitoring. Its product portfolio comprises NIOX MINO and NIOX VERO, hand-held... (more)

Overall

Beta: 0.51
Market Cap (Mil.): kr170.57
Shares Outstanding (Mil.): 155.06
Dividend: --
Yield (%): --

Financials

  AEROb.ST Industry Sector
P/E (TTM): -- 32.73 38.84
EPS (TTM): -1.47 -- --
ROI: -78.58 8.03 18.26
ROE: -436.43 12.97 19.12
Search Stocks

BRIEF-Aerocrine announces expansion of underwriting consortium in pending rights issue

* Aerocrine announces an expansion of the underwriting consortium in the pending rights issue

22 Dec 2014

BRIEF-Aerocrine says terminates discussions of non-binding acquisition offer

* Aerocrine announces termination of discussions of a non-binding offer for acquisition of the company and provides an update on the rights issue

12 Dec 2014

BRIEF-Aerocrine Q3 operating loss shrinks

* Aerocrine ab q3 net sales increased by 24% to sek 38.5m (31.1)

27 Nov 2014

BRIEF-U.S. FDA approved Aerocrine's Niox Vero device

* Aerocrine received notification that the United States Food and Drug Administration (FDA) has granted market clearance for NIOX VERO, the company's next generation device for measuring Fractional exhaled Nitric Oxide (FeNO) levels in the clinical setting

06 Nov 2014

BRIEF-Aerocrine to collaborate with Microsoft to test cloud-based monitoring

STOCKHOLM, Sept 29 - - Aerocrine : * Aerocrine and Microsoft collaborate to test secure, cloud-based remote medical device monitoring Link to press release: http://mb.cision.com/Main/49/9651924/292161.pdf

29 Sep 2014

BRIEF-Aerocrine posts Q2 operating loss

July 24 - Aerocrine : * Q2 - global net sales increased by 19% to SEK 42.5M (35.7)*. adjusted for

24 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$10.00
Provider: GlobalData
$125.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks